Seqens Seqens

X
[{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"NIH\/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by AnaBios

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            This award will support the execution of Investigational New Drug-enabling studies aimed at obtaining Food and Drug Administration approval for subsequent human dosing in a Phase 1 clinical study incliding ANB-504, a lead small molecule dual inhibitor of two sodium channels.

            Lead Product(s): ANB-504

            Therapeutic Area: Neurology Product Name: ANB-504

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $1.7 million Upfront Cash: Undisclosed

            Deal Type: Funding September 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AnaBios provided ex vivo data from human heart tissue to assess the pro-arrhythmic risk of the new NCX1.1 inhibitor, ORM-11372 (developed in Orion Pharma).

            Lead Product(s): ORM-11372

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ORM-11372

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Orion Biotechnology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY